Metsera (MTSR) and Its Peers Critical Contrast

Metsera (NASDAQ:MTSR) is one of 617 publicly-traded companies in the “MED – BIOMED/GENE” industry, but how does it contrast to its rivals? We will compare Metsera to related companies based on the strength of its institutional ownership, profitability, analyst recommendations, earnings, valuation, dividends and risk.

Insider and Institutional Ownership

51.3% of shares of all “MED – BIOMED/GENE” companies are held by institutional investors. 13.7% of shares of all “MED – BIOMED/GENE” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Metsera and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Metsera	N/A	-121.12%	-53.54%
Metsera Competitors	-1,425.24%	-589.70%	-28.85%

Analyst Ratings

This is a summary of recent recommendations for Metsera and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metsera	1	3	4	0	2.38
Metsera Competitors	5935	12242	37727	1175	2.60

Metsera currently has a consensus price target of $55.75, indicating a potential downside of 20.92%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 55.18%. Given Metsera’s rivals stronger consensus rating and higher probable upside, analysts clearly believe Metsera has less favorable growth aspects than its rivals.

Earnings & Valuation

This table compares Metsera and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Metsera	N/A	-$209.13 million	-11.16
Metsera Competitors	$958.53 million	-$45.28 million	11.48

Metsera’s rivals have higher revenue and earnings than Metsera. Metsera is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Metsera rivals beat Metsera on 10 of the 12 factors compared.

About Metsera

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.